ReSPECT-LM Dose Optimization Trial for REYOBIQ™
Plus Therapeutics, Inc. (Nasdaq: PSTV), a pioneering company in targeted radiotherapeutics, is excited to announce the initiation of the ReSPECT-LM dose optimization trial for REYOBIQ™. This groundbreaking trial is focused on optimizing the dosing regimen for REYOBIQ™ (rhenium Re186 obisbemeda), specifically aimed at treating leptomeningeal metastases, a severe condition affecting the central nervous system.
The need for effective treatment options in this area is critical, as leptomeningeal metastases occur in about 5% of metastatic cancer cases, which often leads to poor outcomes. The current median survival rate for patients is between 2 and 6 months, highlighting the urgency for innovative therapeutic solutions.
Overview of the Trial Design
This innovative trial draws from the encouraging results of the previously completed Phase 1 trial and is designed in alignment with the FDA’s Project Optimus. The central objective is to determine the safety, tolerability, and efficacy of REYOBIQ™ when administered via intraventricular catheter at carefully defined intervals. By addressing the safety parameters and identifying the optimal dosing schedule, Plus Therapeutics aims to pave the way for future registrational trials.
Trial Objectives and Patient Enrollment
In total, the ReSPECT-LM trial plans to enroll up to 24 patients, assessing the effects of REYOBIQ™ regimens. Each patient cohort will receive a recommended Phase 2 dose of 44.1 mCi, distributed across three dosing intervals. This careful cohort structure will enable a thorough evaluation of both responses to treatment and safety, thus providing invaluable data for subsequent trials.
Key Components of the Study
The trial will not only focus on safety and tolerability but will also measure essential efficacy-related endpoints, including objective response rate (ORR) and neurologic progression-free survival (PFS). Through continuous monitoring of cerebrospinal fluid (CSF) tumor cell counts, the trial aims to yield critical insights regarding pharmacodynamics and therapeutic effectiveness.
Initially, the trial will be confined to two esteemed cancer centers in Texas, with the potential to expand to additional locations as needed. This strategic choice ensures a quality-focused enrollment process while maintaining rigorous safety standards.
Insights from Previous Trials
The ReSPECT-LM trial builds upon promising findings from the Company’s earlier single-dose escalation trial. Notable results included a clinically significant benefit rate of 76%, with many patients experiencing stable disease or partial responses.
Further Investigations and Future Directions
Moreover, pharmacodynamic indicators such as increased T-cell activity observed during RNA sequencing highlight the potential of REYOBIQ™ to drive immune responses against malignancies. The Company’s commitment to providing cutting-edge cancer treatments is further reflected in their continuous efforts to present trial data at major conferences.
About REYOBIQ™ and Company Background
REYOBIQ™ represents a novel approach to cancer treatment, utilizing a targeted radiotherapy mechanism aimed at minimizing off-target effects, which are common in traditional cancer treatments. By delivering a specific, high-dose radiation to affected areas, Plus Therapeutics aims to optimize therapeutic outcomes for patients battling central nervous system cancers.
Headquartered in Houston, Texas, Plus Therapeutics is dedicated to advancing therapies that enhance the quality of life for individuals with challenging-to-treat cancers. The Company actively pursues innovative solutions, developing a robust pipeline that includes ongoing trials for recurrent glioblastoma and pediatric brain cancers.
The ReSPECT-LM trial is generously supported by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT), which stands as one of the world's leading public funding sources for cancer research initiatives.
Frequently Asked Questions
What is the focus of the ReSPECT-LM trial?
The trial aims to optimize the dosing schedule of REYOBIQ™ for treating leptomeningeal metastases and evaluate its safety and efficacy.
How many patients will be enrolled in the trial?
Up to 24 patients will be enrolled across three dosing cohorts to assess the treatment's effects.
What makes REYOBIQ™ different from other cancer treatments?
REYOBIQ™ is a targeted radiotherapy designed to deliver high doses directly to cancer cells, minimizing damage to surrounding healthy tissue.
Why is leptomeningeal metastasis significant?
Leptomeningeal metastases are a severe complication of cancer with limited treatment options, significantly affecting patient survival rates.
Is Plus Therapeutics involved in other clinical trials?
Yes, Plus Therapeutics is also conducting trials for recurrent glioblastoma and pediatric brain cancers, aiming to broaden its impact in cancer treatment.
